In the phase 3 REFLECT trial, lenvatinib, an oral multikinase inhibitor, showed non-inferior survival compared with sorafenib in patients with untreated, unresectable hepatocellular carcinoma (HCC). However, the assessment of baseline liver function as a prognostic factor for patients with unresectable HCC receiving lenvatinib had not yet been investigated. In a post hoc analysis of the trial, a team of researchers led by Arndt Vogel, MD, Professor of Gastrointestinal Oncology at Hannover Medica...
In advanced hepatocellular carcinoma (HCC), nivolumab (Opdivo®, Bristol-Meyers Squibb) is superior to sorafenib (Nexavar®, Bayer) with regard to health-related quality of life (HRQOL), according to results of the phase 3 CheckMate 459 trial to be reported on Friday at the 2020 Gastrointestinal Cancers Symposium.For CheckMate 459, 743 patients with advanced HCC were randomized in a 1:1 ratio to receive nivolumab or sorafenib. The researchers reported in September at the 44th European Society for...
With a median overall survival of only 11 months, intrahepatic cholangiocarcinoma (IHC) warrants more effective therapies. Researchers recently discovered that a regimen of hepatic arterial infusion of floxuridine plus systemic gemcitabine and oxaliplatin produces promising outcomes in patients with unresectable IHC.In this phase 2 clinical trial, 38 patients with histologically confirmed, unresectable IHC were enrolled and treated. Participants with resectable metastatic disease to regional lym...
Biliary tract cancers have a dismal prognosis, with five-year survival rates ranging from 5% to 15%. In their publication in JAMA Oncology, Sarah S. Jackson, PhD, and colleagues report that aspirin increases survival in biliary tract cancers, including gallbladder cancer, cholangiocarcinoma, ampulla of Vater cancer, and overlapping lesions of the biliary tract. In this interview with i3 Health, Dr. Jackson discusses the potential ramifications of her study's findings.What led you to pursue this...
Researchers have now revealed that aspirin can increase the dismal survival chances for biliary tract cancers.Because these rare diseases may not produce symptoms until the later stages, 60% to 70% of patients with biliary tract cancers present with later-stage disease. Less than 10% have resectable tumors at the time of diagnosis, and 50% present with lymph node metastasis. As a result, the median survival is under a year, with five-year survival rates ranging from 5% to 15%. "There is a criti...